COMPANY

Magnus Medical

HQ: Burlingame, CA source · magnusmedical.com ↗ · West Coast

FDA-cleared device company Clinical Phase 3

2 open jobs · last seen Oct 23, 2026 · 7 sources

Keywords: major depressive disorder psychiatry Major Depressive Episode Suicidal Ideation Postpartum Depression Active SAINT Stimulation SAINT Neuromodulation System SAINT® Neuromodulation System (NMS)

Profile checked Oct 10, 2026

2Open jobs 4Trials (company is sponsor)3NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Staff Software Engineer, Neuronavigation and Autonomy	Burlingame, California	Not stated	Oct 11, 2026
Senior Test and Design Assurance Engineer	Burlingame, California	Not stated	Oct 11, 2026

See all 2 jobs

Timeline

Nov 1, 2025 Trial start Not phased (device or behavioral study): SAINT in Postpartum Depression (PPD) source ↗
Jun 30, 2024 Trial start Phase 2/Phase 3: The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition source ↗
Jun 30, 2024 Trial start Phase 2/Phase 3: SAINT for MDD in an Inpatient Setting Follow-on source ↗
Apr 6, 2023 Trial start —: Open Label Optimization Study source ↗

Upcoming milestones

Oct 15, 2026 (ESTIMATED) · · Open Label Optimization Study · NCT05819021
Apr 30, 2029 (ESTIMATED) · Not phased · SAINT in Postpartum Depression (PPD) · NCT07210255

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07210255	SAINT in Postpartum Depression (PPD)	Not phased (device or behavioral study)	Recruiting	Nov 1, 2025	Apr 30, 2029 (estimated)
NCT05819021	Open Label Optimization Study	Not listed	Active, not recruiting	Apr 6, 2023	Oct 15, 2026 (estimated)
NCT03693105	The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition	Phase 2/Phase 3	Terminated	Jun 30, 2024	Mar 6, 2025 (actual)
NCT06462820	SAINT for MDD in an Inpatient Setting Follow-on	Phase 2/Phase 3	Terminated	Jun 30, 2024	Mar 6, 2025 (actual)

NIH awards 3

Annual award amounts. Total $863K.

Jul 25, 2024 NIH award 3R01MH125160-04S1 FY2024: $86,807 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BENTZLEY, BRANDON S; recipient as written: MAGNUS MEDICAL INC, BURLINGAME, CA. The Effects of Stanford Accelerate source ↗
Feb 5, 2024 NIH award 5R01MH125160-04 FY2024: $377,647 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BENTZLEY, BRANDON S; recipient as written: MAGNUS MEDICAL INC, BURLINGAME, CA. The Effects of Stanford Accelerated source ↗
Mar 2, 2023 NIH award 7R01MH125160-03 FY2023: $399,033 awarded for that fiscal year; activity R01 (OTHER_NIH); PI BENTZLEY, BRANDON S; recipient as written: MAGNUS MEDICAL INC, BURLINGAME, CA. The Effects of Stanford Accelerated source ↗

Open jobs 2

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Staff Software Engineer, Neuronavigation and Autonomy	Burlingame, California	Not stated	Oct 11, 2026	Senior
Senior Test and Design Assurance Engineer	Burlingame, California	Not stated	Oct 11, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Magnus Medical on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18